SmadMin-Therapeutics B.V.

We Never Give Up!

SmadMin-Therapeutics B.V. is a startup company led by Prof. Dr. Sheila Krishnadath.
SmadMinx owns proprietary novel therapeutics specifically meant to be furhter developed for the prevention of the return of cancer in the body. In particular patients, who have been treated for  aggressive malignancies within the Gastro-intestinal tract may benefit from these therapeutics. The SmadMinx molecules are low molecular weight Llama antibodies (VHH) with high specificity against specific growth factors, which are critical in inducing cancer cell replication and cancer spread. In preclinical studies, the potential effect of  the SmadMin therapeutics was already demonstrated for the prevention of lung and liver metastasis in an aggressive cancer subtype, which carries a specific mutation. This means that a specific subgroup of cancer patients may highly benefit from these drugs, for instance when given as an preventive therapy after the initial treatment (e.g. operation) of the primary cancer.

 

PROBLEM

Gastro-intestinal cancers such as esophageal, gastric and pancreatic cancers are still among the top five gastrointestinal malignancies responsible for millions of deaths on a yearly base. Although, surgery chemo-and radiotherapies are effective for treatment of the primary tumor,  more than 80% of cases will still die within 1-2 years, due to return of disease because of cancer recurrence and cancer spread in the body (metastasis). Developing highly specific patient tailored targeted therapies to prevent tumor spread is therefore a highly desired and urgent unmet medical need.

 

GOAL

The goal of SmadMinx is to apply  the novel targeted therapeutics to inhibit the stroma-cancer-cross-talk in order to prevent cancer spread and cancer return in the patient’s body.

...interested in more?
reach out to us